Critical Reviews in Oncology / Hematology
Volume 77, Issue 2 , Pages 87-99 , February 2011

Adjuvant endocrine therapy in postmenopausal breast cancer patients: Does hormone receptor status influence decision-making?

  • Fabio Puglisi

      Affiliations

    • Corresponding Author InformationCorresponding author at: Department of Medical Oncology, University Hospital of Udine, Piazzale S.M. Misericordia, 33100 Udine, Italy. Tel.: +39 0 432 559304 09; fax: +39 0 432 559305.
    • ,
  • Alessandro Marco Minisini

,Accepted 7 January 2010.

References 

  1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–592
  2. What Role Do Hormones Play in Breast Cancer Treatment? www.breastcancer.org/treatment/hormonal/what_is_it/hormone_role.jsp.[accessed 08.31.2009].
  3. Nadji M, GomezFernandez C, GanjeiAzar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: Experience with 5,993 breast cancers. Am J Clinical Pathol. 2005;123:21–27
  4. Singh RR, Kumar R. Steroid hormone receptor signaling in tumorigenesis. J Cell Biochem. 2005;96:490–505
  5. Gao X, Nawaz Z. Progesterone receptors - animal models and cell signaling in breast cancer: Role of steroid receptor coactivators and corepressors of progesterone receptors in breast cancer. Breast Cancer Res. 2002;4:182–186
  6. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A. 2000;97:1032–1037
  7. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol. 2003;17:575–588
  8. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005;11:865s–870s
  9. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  10. Susnjar S, Neskovic-Konstantinovic Z, Kezic I, Vasovic S, Lakisevic J. The influence of steroid receptor (SR) content on disease outcome in early breast cancer patients treated with adjuvant endocrine therapy. Breast. 2005;14(Suppl. 1):S37;[abstract P77]
  11. Yu KD, Liu GY, Di GH, Wu J, Lu JS, Shen KW, et al. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. Breast. 2007;16:307–315
  12. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97:1254–1261
  13. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  14. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  15. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–570
  16. Cazzaniga ME, Mustacchi G, Pronzato P, De Matteis A, Di Costanzo F, Floriani I, et al. Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study. Ann Oncol. 2007;18:1976–1980
  17. Aiello EJ, Buist DS, Wagner EH, Tuzzio L, Greene SM, Lamerato LE, et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008;107:397–403
  18. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25:3846–3852
  19. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005;23:7512–7517
  20. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. National Cancer Institute of Canada Clinical Trials Group MA.17. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol. 2007;25:2006–2011
  21. Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel J-M, Paridaens R, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res. 2009;69(Suppl.):67s;[abstract 15]
  22. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9:606–616
  23. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–2746
  24. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998;52:227–237
  25. Hortobagyi GN, Kau SW, Buzdar AU, Theriault RL, Booser DJ, Gwyn K, et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis?. J Clin Oncol. 2004;22(14S):[abstract 585]
  26. Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, et al. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol. 2004;22:1769–1770
  27. MacGrogan G, de Mascarel I, Sierankowski G, Mauriac L, Debled M, Durand M, et al. Time for reappraisal of progesterone-receptor testing in breast cancer management. J Clin Oncol. 2005;23:2870–2871
  28. Colomer R, Beltran M, Dorcas J, Cortes-Funes H, Hornedo J, Valentin V, et al. It is not time to stop progesterone receptor testing in breast cancer. J Clin Oncol. 2005;23:3868–3870
  29. Colozza M, Larsimont D, Piccart MJ. Progesterone receptor testing: not the right time to be buried. J Clin Oncol. 2005;23:3867–3868
  30. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007;25:4772–4778
  31. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  32. Dhesy-Thind B, Pritchard KI, Messersmith H, O’Malley F, Elavathil L, Trudeau M. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat. 2008;109:209–229
  33. Penault-Llorca F, Vincent-Salomon A, Mathieu MC, Trillet-Lenoir V, Khayat D, Marty M, et al. Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC). J Clin Oncol. 2005;23(16S):69s;[abstract 764]
  34. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?. Clin Cancer Res. 2005;11:4835–4842
  35. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002;20:1467–1472
  36. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451–1467
  37. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973–1979
  38. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A’Hern R, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006;17:818–826
  39. Geisler J, Lønning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol. 2005;95:75–81
  40. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:108–192[Erratum in: N Engl J Med 2004; 351:2461. N Engl J Med 2006; 355:1746. van de Velde, Cornelius [added]]
  41. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26:1671–1676
  42. Geisler J, Helle H, Ekse D, Duong NK, Evans DB, Nordbø Y, et al. Letrozole is superior to anastrozole suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res. 2008;14:6330–6335
  43. Mansell J, Monypenny IJ, Skene AI, Abram P, Carpenter R, Gattuso JM, et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2009;117:91–98
  44. Lamerato L, Havstad S, Gandhi S, Jones D, Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. J Clin Oncol. 2005;23(16S):62s;[abstract 738]
  45. Lê MG, Arriagada R, Spielmann M, Guinebretiére J-M, Rochard F. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer. 2002;94:2813–2820
  46. Elder EE, Kennedy CW, Gluch L, Carmalt HL, Janu NC, Joseph MG, et al. Patterns of breast cancer relapse. Eur J Surg Oncol. 2006;32:922–927
  47. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361:766–776
  48. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell’Orto P, Del Curto B, Henriksen KL, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008;9:23–28
  49. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486–492
  50. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008;26:1059–1065
  51. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53
  52. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008;26:5569–5575
  53. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001;12:1527–1532
  54. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–3816
  55. Dixon JM, Renshaw L, Macaskill EJ, Young O, Murray J, Cameron D, et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat. 2009;113:145–151
  56. Young O, Murray J, Renshaw L, Evans DB, Cameron D, Dowsett M, et al. Neoadjuvant letrozole is equally effective in Her 2 positive and negative breast cancers. Breast Cancer Res Treat. 2004;8(Suppl. 1):S38;[abstract 411]
  57. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003;63:6523–6531
  58. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, et al. Estrogen-independent proliferation is present in estrogen-dependent HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006;24:3019–3025
  59. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate PReoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–5116
  60. Dixon JM, Jackson J, Hills M, Renshaw L, Cameron DA, Anderson TJ, et al. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer. 2004;40:2742–2747
  61. Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100:1380–1388
  62. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomised trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271
  63. Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007;102:43–49
  64. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27:5529–5537
  65. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66:1630–1639
  66. Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27:5538–5546
  67. Letrozole and lapatinib in treating postmenopausal women with stage I, stage II, or stage III breast cancer that can be removed by surgery. www.clinicaltrials.gov/ct/show/NCT00499681 [accessed 08.31.2009].
  68. Letrozole in combination with lapatinib in neoadjuvant treatment of early breast cancer. www.clinicaltrials.gov/ct/show/NCT00422903 [accessed 08.31.2009].
  69. Frassoldati A, Guarneri V, Bottini A, Cagossi K, Cavanna L, Bisagni G. Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study. J Clin Oncol. 2008;26(15S):36S;[abstract 623]
  70. Hauge-Evans AC, Evans DB, Dowsett M, Martin L-A. Combining the RTK inhibitor AEE788 with tamoxifen or letrozole results in enhanced growth inhibition of hormone-dependent human breast cancer cells. Breast Cancer Res Treat. 2004;88(Suppl. 1):S32;[abstract 308]
  71. Farmer I, Pancholi S, Thornhill A, Evans DB, Lane HA, Dowsett M, et al. Effectiveness of RAD001 (everolimus) in combination with endocrine therapy varies with cell phenotype. Breast Cancer Res Treat. 2007;106(Suppl. 1):S81;[abstract 1115]
  72. Baselga J. Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer. J Clin Oncol. 2008;26(15S):13s;[abstract 530]
  73. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–1481
  74. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol. 2009;20:1319–1329
  75. Anon. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996; 14:2843-77.
  76. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619–629
  77. Pestalozzi BC, Luporsi-Gely E, Jost LM, Bergh J. ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol. 2005;16(Suppl. 1):i7–i9
  78. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Breast Cancer. Version 1.2009. www.nccn.org/professionals/physician_gls/PDF/breast.pdf [accessed 08.31.09].

PII: S1040-8428(10)00007-7

doi: 10.1016/j.critrevonc.2010.01.006

Critical Reviews in Oncology / Hematology
Volume 77, Issue 2 , Pages 87-99 , February 2011

Article Tools

* Image Usage & Resolution